01 — At a Glance
The Chemical Company That Caught a Cold (But Swears It’s Just Allergies)
- 52-Week High / Low₹2,114 / ₹822
- Q3 FY26 Revenue₹597 Cr
- Q3 FY26 PAT₹39.2 Cr
- Q3 EPS (FY26)₹9.07
- Annualised EPS (Q3×4)₹36.28
- Book Value₹487
- Price to Book1.78x
- Debt / Equity0.26x
- Return 1-Year-54.7%
- Return 6-Month-51.6%
What Happened Here? Epigral logged ₹597 crore in Q3 revenue, down -7.46% QoQ. Net profit crashed -62.2% YoY to ₹39.2 crore. The OPM collapsed to 17% from 28% last quarter. Why? CPVC inventory became more expensive than a Mumbai apartment, PVC prices tanked like demonetized currency, and management had to take the haircut. The stock fell 51.6% in six months. But here’s the plot twist: management says Q4 is “inflection quarter.” Let’s see if they’re right, or just selling us hope with a chemical smell.
02 — Introduction
The Company That Decided to Play both Commodity AND Specialty. Badly.
Epigral Limited, formerly Meghmani Finechem, is India’s integrated chemical manufacturer that makes caustic soda like everyone else, but also claims to be India’s sole producer of Epichlorohydrin. That’s like saying you’re an auto company that makes cars AND bicycles. Technically true. Strategically confusing.
For those keeping score at home: caustic soda is what happens when you hit chlorine with seawater. Epichlorohydrin is what happens when you’re bored and decide to make epoxy resins sound sexy. CPVC is what your plumber uses to avoid PVC’s drama. Chloromethanes are what happen when you tell methane to make friends with chlorine. And hydrogen peroxide is, well, your mother’s hair bleach. The company makes all of these. From a single facility. In Dahej, Gujarat. Which is either genius or insane. The market is still voting.
Revenue composition: 56% from Derivatives & Specialty Chemicals (up from 25% in FY22). 44% from Chlor-alkali (down from 75% in FY22). The plan? Flip this to 70:30 by FY27. The problem? Getting there means betting on CPVC demand, riding out the commodity cycle, and not blowing up the balance sheet. In Q3, they proved they could execute capex. They did NOT prove they could time the market.
The company raised ₹333 crore via QIP in October 2024. Paid down debt. Approved ₹780 crore capex to double CPVC and Epichlorohydrin capacity by H1 FY27. And promptly got punched in the face when PVC prices collapsed and their inventory became a liability with the IQ of a kumquat.
03 — Business Model: What the Hell Are They Making?
Caustic Soda. CPVC. Epichlorohydrin. And the Fear of Missing Out on Everything.
Epigral’s business is backward-integrated vertigo. They buy chlorine (from their own electrochemical unit), hydrogen (produced on-site), and base chemicals. Then they either sell the chlorine to PVC makers, or keep it to make Chloromethanes (MDC, Chloroform, Carbon Tetrachloride). Or they turn it into Epichlorohydrin. Or CPVC. Or caustic potash. Or hydrogen peroxide. It’s like they’re playing 4D chess while everyone else is playing checkers. Except half the time they’re losing at checkers.
The advantage: integrated, low-cost model. Chlorine is a byproduct of caustic production, so they’re not buying it at market rates. They produce 400 KTPA of caustic soda (4th largest in India), 75 KTPA of CPVC (expanding to 150 KTPA), 50 KTPA of Epichlorohydrin (expanding to 100 KTPA). The utilization: 78% in Q3 FY26. Not stellar. Not terrible. Just… there. Like your uncle at a family gathering.
The disadvantage: they’re exposed to EVERY cycle simultaneously. When caustic tanked YoY by 12-45% in FY24, they felt it. When PVC collapsed in Q3, CPVC inventory became a dumpster fire. When ECH demand softens in Europe (it did), they noticed (they did). In their Feb 2026 concall, management literally said: “This kind of situation was never seen… PVC pressure… in a very short period.” Translation: “We didn’t see this coming, but pretend we’re not shocked.”
Caustic Soda400 KTPA4th Largest in India
CPVC Resin75→150 KTPACapacity (Expanding)
Epichlorohydrin50→100 KTPACapacity (Expanding)
Management Confession (Feb 2026 Concall): “PVC price was going down drastically… we have a higher capacity of PVC in the stock… major reason… high inventory cost.” Translation: They loaded up on CPVC when they thought PVC would hold steady. It didn’t. They’re now eating the loss on their balance sheet. The FY26 capex budget? Already spent ₹337 crore of their ₹780 crore expansion plan. They’re committed.
💬 If management says Q4 is an “inflection quarter,” would you trust them? Or would you wait for the March results to confirm? Drop your view in comments.
04 — Financials Overview
Q3 FY26: When Your OPM Decides to Play Limbo
Result type: Quarterly Results | Q3 FY26 EPS: ₹9.07 | Annualised EPS (Q3×4): ₹36.28 | FY26 TTM EPS (estimated): ₹78.27
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 597 | 645 | 587 | -7.46% | +1.7% |
| Operating Profit | 103 | 183 | 132 | -43.7% | -21.9% |
| OPM % | 17% | 28% | 23% | -1100 bps | -600 bps |
| PAT | 39.2 | 104 | 51 | -62.2% | -23.1% |
| EPS (₹) | 9.07 | 24.0 | 11.94 | -62.2% | -24.0% |
Let’s Talk About This OPM Collapse: Operating profit went from ₹183 Cr (Q3 FY25) to ₹103 Cr (Q3 FY26). That’s not cyclical. That’s cardiac arrest. Management’s concall breakdown: “lower realizations, rising raw material costs and higher cost inventory.” Translation: PVC crashed. They were holding CPVC at higher cost. The lag between PVC price cuts and CPVC adjustments? 1-1.5 months normally. In Q3, it was a dagger. Management projects margins recovering to 21–23% by Q4 as PVC prices rise and inventory normalizes. Are they right? Ask again in April.
05 — Valuation: Fair Value Range
Is This A Bargain Or Just Expensive Disappointment?
